Patterns of care for prostate cancer radiotherapy-results from a survey among German-speaking radiation oncologists

被引:6
作者
Vogel, Marco M. E. [1 ,2 ]
Dewes, Sabrina [1 ]
Sage, Eva K. [1 ]
Devecka, Michal [1 ]
Gschwend, Jurgen E. [3 ]
Schiller, Kilian [1 ]
Combs, Stephanie E. [1 ,2 ,4 ]
机构
[1] Tech Univ Munich TUM, Klinikum Rechts Isar, Dept Radiat Oncol, Ismaninger Str 22, D-81675 Munich, Germany
[2] Helmholtz Zentrum Munchen, Dept Radiat Sci DRS, Inst Radiat Med IRM, Neuherberg, Germany
[3] Tech Univ Munich TUM, Klinikum Rechts Isar, Dept Urol, Munich, Germany
[4] Deutsch Konsortium Translat Krebsforsch DKTK, Partner Site Munich, Munich, Germany
关键词
Prostate carcinoma; Treatment pathways; Questionnaire; German-speaking countries; Radiation therapy;
D O I
10.1007/s00066-020-01738-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Emerging moderately hypofractionated and ultra-hypofractionated schemes for radiotherapy (RT) of prostate cancer (PC) have resulted in various treatment options. The aim of this survey was to evaluate recent patterns of care of German-speaking radiation oncologists for RT of PC. Methods We developed an online survey which we distributed via e-mail to all registered members of the German Society of Radiation Oncology (DEGRO). The survey was completed by 109 participants between March 3 and April 3, 2020. For evaluation of radiation dose, we used the equivalent dose at fractionation of 2 Gy with alpha/beta = 1.5 Gy, equivalent dose (EQD2 [1.5 Gy]). Results Median EQD2(1.5 Gy) for definitive RT of the prostate is 77.60 Gy (range: 64.49-84.00) with median single doses (SD) of 2.00 Gy (range: 1.80-3.00), while for postoperative RT of the prostate bed, median EQD2(1.5 Gy) is 66.00 Gy (range: 60.00-74.00) with median SD of 2.00 Gy (range: 1.80-2.00). For definitive RT, the pelvic lymph nodes (LNs) are treated in case of suspect findings in imaging (82.6%) and/or according to risk formulas/tables (78.0%). In the postoperative setting, 78.9% use imaging and 78.0% use the postoperative tumor stage for LN irradiation. In the definitive and postoperative situation, LNs are irradiated with a median EQD2(1.5 Gy) of 47.52 Gy with a range of 42.43-66.00 and 41.76-62.79, respectively. Conclusion German-speaking radiation oncologists' patterns of care for patients with PC are mainly in line with the published data and treatment recommendation guidelines. However, dose prescription is highly heterogenous for RT of the prostate/prostate bed, while the dose to the pelvic LNs is mainly consistent.
引用
收藏
页码:962 / 970
页数:9
相关论文
共 42 条
  • [1] Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection
    Abdollah, Firas
    Dalela, Deepansh
    Sood, Akshay
    Keeley, Jacob
    Alanee, Shaheen
    Briganti, Alberto
    Montorsi, Francesco
    Peabody, James O.
    Menon, Mani
    [J]. EUROPEAN UROLOGY, 2018, 74 (03) : 253 - 256
  • [2] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial
    Aluwini, Shafak
    Pos, Floris
    Schimmel, Erik
    van Lin, Emile
    Krol, Stijn
    van der Toorn, Peter Paul
    de Jager, Hanja
    Dirkx, Maarten
    Alemayehu, Wendimagegn Ghidey
    Heijmen, Ben
    Incrocci, Luca
    [J]. LANCET ONCOLOGY, 2015, 16 (03) : 274 - 283
  • [3] ELECTIVE PELVIC IRRADIATION IN STAGE A2, B CARCINOMA OF THE PROSTATE - ANALYSIS OF RTOG-77-06
    ASBELL, SO
    KRALL, JM
    PILEPICH, MV
    BAERWALD, H
    SAUSE, WT
    HANKS, GE
    PEREZ, CA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 15 (06): : 1307 - 1316
  • [4] Salvage reirradiation for local prostate cancer recurrence after I radiation therapy. For who? When? How?
    Baty, M.
    Crehange, G.
    Pasquier, D.
    Palard, X.
    Deleuze, A.
    Gnep, K.
    Key, S.
    Beuzit, L.
    Castelli, J.
    de Crevoisier, R.
    [J]. CANCER RADIOTHERAPIE, 2019, 23 (6-7): : 541 - 558
  • [5] Guidelines for primary radiotherapy of patients with prostate cancer
    Boehmer, Dirk
    Maingon, Philippe
    Poortmans, Philip
    Baron, Marie-Helene
    Miralbell, Raymond
    Remouchamps, Vincent
    Scrase, Christopher
    Bossi, Alberto
    Bolla, Michel
    [J]. RADIOTHERAPY AND ONCOLOGY, 2006, 79 (03) : 259 - 269
  • [6] Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
    Bolla, Michel
    Maingon, Philippe
    Carrie, Christian
    Villa, Salvador
    Kitsios, Petros
    Poortmans, Philip M. P.
    Sundar, Santhanam
    van der Steen-Banasik, Elzbieta M.
    Armstrong, John
    Bosset, Jean-Francois
    Herrera, Fernanda G.
    Pieters, Bradley
    Slot, Annerie
    Bahl, Amit
    Ben-Yosef, Rahamim
    Boehmer, Dirk
    Scrase, Christopher
    Renard, Laurette
    Shash, Emad
    Coens, Corneel
    van den Bergh, Alphonsus C. M.
    Collette, Laurence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1748 - +
  • [7] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
    Brand, Douglas H.
    Tree, Alison C.
    Ostler, Peter
    van der Voet, Hans
    Loblaw, Andrew
    Chu, William
    Ford, Daniel
    Tolan, Shaun
    Jain, Suneil
    Martin, Alexander
    Staffurth, John
    Camilleri, Philip
    Kancherla, Kiran
    Frew, John
    Chan, Andrew
    Dayes, Ian S.
    Henderson, Daniel
    Brown, Stephanie
    Cruickshank, Clare
    Burnett, Stephanie
    Duffton, Aileen
    Griffin, Clare
    Hinder, Victoria
    Morrison, Kirsty
    Naismith, Olivia
    Hall, Emma
    van As, Nicholas
    [J]. LANCET ONCOLOGY, 2019, 20 (11) : 1531 - 1543
  • [8] Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial
    Carrie, Christian
    Hasbini, Ali
    de Laroche, Guy
    Richaud, Pierre
    Guerif, Stephane
    Latorzeff, Igor
    Supiot, Stephane
    Bosset, Mathieu
    Lagrange, Jean-Leon
    Beckendorf, Veronique
    Lesaunier, Francois
    Dubray, Bernard
    Wagner, Jean-Philippe
    Tan Dat N'Guyen
    Suchaud, Jean-Philippe
    Crehange, Gilles
    Barbier, Nicolas
    Habibian, Muriel
    Ferlay, Celine
    Fourneret, Philippe
    Ruffion, Alain
    Dussart, Sophie
    [J]. LANCET ONCOLOGY, 2016, 17 (06) : 747 - 756
  • [9] Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer
    Cuccia, Francesco
    Nicosia, Luca
    Mazzola, Rosario
    Figlia, Vanessa
    Giaj-Levra, Niccolo
    Ricchetti, Francesco
    Rigo, Michele
    Vitale, Claudio
    Corradini, Stefanie
    Ruggieri, Ruggero
    Alongi, Filippo
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (07) : 628 - 636
  • [10] Androgen suppression and radiation vs radiation alone for prostate cancer - A randomized trial
    D'Amico, Anthony V.
    Chen, Ming-Hui
    Renshaw, Andrew A.
    Loffredo, Marian
    Kantoff, Philip W.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (03): : 289 - 295